Oxford Biomedica (LON:OXB) Hits New 52-Week High - Time to Buy?

Key Points

• Oxford Biomedica recently reached a new 52-week high of GBX 655 ($8.71), with the stock last trading at GBX 653 ($8.68).
• Analysts have varying opinions on the stock, with Royal Bank of Canada raising its price target to GBX 930, while JPMorgan Chase reduced its target from GBX 490 to GBX 400.
• Insider transactions included a significant purchase of 67,000 shares by Roch Doliveux for £301,500, indicating confidence in the company's prospects.

Shares of Oxford Biomedica plc (LON:OXB - Get Free Report) hit a new 52-week high on Thursday . The stock traded as high as GBX 655 ($8.71) and last traded at GBX 653 ($8.68), with a volume of 248510 shares trading hands. The stock had previously closed at GBX 648 ($8.62).

Analysts Set New Price Targets

A number of analysts recently weighed in on OXB shares. Royal Bank Of Canada lifted their price target on Oxford Biomedica from GBX 800 to GBX 930 and gave the company an "outperform" rating in a research note on Tuesday, August 26th. Canaccord Genuity Group restated a "buy" rating and issued a GBX 451 price target on shares of Oxford Biomedica in a research note on Tuesday. Peel Hunt restated a "buy" rating and issued a GBX 451 price target on shares of Oxford Biomedica in a research report on Friday, August 1st. Finally, JPMorgan Chase & Co. dropped their price target on Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating for the company in a research report on Tuesday, July 15th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Oxford Biomedica has an average rating of "Moderate Buy" and a consensus target price of GBX 558.

Oxford Biomedica Price Performance

The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67. The company has a 50-day moving average price of GBX 549.81 and a 200-day moving average price of GBX 398.39. The firm has a market capitalization of £784.95 million, a PE ratio of -1,802.87 and a beta of 1.09.

Insider Buying and Selling at Oxford Biomedica

In other Oxford Biomedica news, insider Roch Doliveux bought 67,000 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was purchased at an average cost of GBX 450 per share, for a total transaction of £301,500. Also, insider Dame Kay Davies sold 4,563 shares of the company's stock in a transaction on Monday, August 18th. The shares were sold at an average price of GBX 500, for a total value of £22,815. Corporate insiders own 41.90% of the company's stock.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.